Evidence map›Paper›PMID 38733995›Full record

ArticleStructure (London, England : 1993)2024

Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules.

Rhoda Tano-Menka, Nishant K Singh, Itai Muzhingi, Xiaolong Li, Michael V Mandanas, Clarety Kaseke, Charles R Crain, Angela Zhang, Funsho J Ogunshola, Liza Vecchiarello and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Structure (London, England : 1993), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. NK-like and networked CD8bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rhoda Tano-MenkaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Nishant K SinghRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Itai MuzhingiRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Xiaolong LiRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; The First Affiliated School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230027, China.
Michael V MandanasKoch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02142, USA.
Clarety KasekeRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Charles R CrainRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Angela ZhangRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Funsho J OgunsholaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Liza VecchiarelloRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Alicja Piechocka-TrochaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Arman BashirovaBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Michael E BirnbaumRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02142, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Mary CarringtonRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Bruce D WalkerRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Institute for Medical Engineering and Science and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Gaurav D GaihaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: ggaiha@mgh.harvard.edu.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Mark Joseph Daly · 1991 to 2026
$35.3M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
Molecular genetics and population studies of the KIR and HLA gene complexesZIABC010792 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$7.8M
Harnessing Highly Networked HLA-E-Restricted CTL Epitopes to Achieve a Broadly Effective HIV CureDP1DA058476 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI Gaurav Das Gaiha · 2023 to 2026
$4.7M
Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA RepliconsR01AI176533 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Gaurav Das Gaiha · 2023 to 2026
$3.5M
Exploiting Highly Networked CTL Epitopes to Achieve a Functional HIV CureDP2AI154421 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GAIHA, GAURAV DAS · 2020 to 2024
$2.7M
NCI NIH HHS 75N91019D00024NIAID NIH HHS DP2 AI154421NIAID NIH HHS R01 AI176533NIAID NIH HHS UM1 AI144462NIAID NIH HHS UM1 AI164560NIDA NIH HHS DP1 DA058476NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

Immunogenetic studies have shown that specific HLA-B residues (67, 70, 97, and 156) mediate the impact of HLA class I on HIV infection, but the molecular basis is not well understood. Here we evaluate the function of these residues within the protective HLA-B

Indexed as

HLA-B AntigensProtein BindingReceptors, Antigen, T-CellBinding SitesCD8-Positive T-LymphocytesHIV-1HIV InfectionsHumansModels, MolecularPeptidesPolymorphism, GeneticProtein StabilityReceptors, KIR3DL1HLA-B*57:01 antigenHLA-B AntigensKIR3DL1 protein, humanPeptidesReceptors, Antigen, T-CellReceptors, KIR3DL1CD8(+) T cellsHIVHLAimmunogeneticsKIRNK cellsTCR

Identifiers

PMID38733995
PMCPMC11329236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.